1. Hu, Jiao, Yu, Anze, Othmane, Belaydi, Chen, Jinbo, Zu, Xiongbing. 2021. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. In Theranostics, 11, 3089-3108. doi:10.7150/thno.53649. https://pubmed.ncbi.nlm.nih.gov/33537076/
2. Li, Tian-Jiao, Jin, Kai-Zhou, Li, Hao, Yu, Xian-Jun, Wu, Wei-Ding. 2022. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. In Cancer letters, 530, 142-155. doi:10.1016/j.canlet.2022.01.026. https://pubmed.ncbi.nlm.nih.gov/35077803/
3. Liang, Haifeng, Chen, Qing, Hu, Zhichao, Jiang, Libo, Dong, Jian. . Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis. In Annals of translational medicine, 10, 281. doi:10.21037/atm-22-764. https://pubmed.ncbi.nlm.nih.gov/35434017/
4. Xu, Ji-Li, Guo, Yong. 2021. A comprehensive analysis of different gene classes in pancreatic cancer: SIGLEC15 may be a promising immunotherapeutic target. In Investigational new drugs, 40, 58-67. doi:10.1007/s10637-021-01176-5. https://pubmed.ncbi.nlm.nih.gov/34515878/
5. Zhang, Yongxing, Sun, Hangxiang, Huang, Fei, Sun, Xuxu, Ye, Zhaoming. . The chromatin remodeling factor Arid1a cooperates with Jun/Fos to promote osteoclastogenesis by epigenetically upregulating Siglec15 expression. In Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 39, 775-790. doi:10.1093/jbmr/zjae042. https://pubmed.ncbi.nlm.nih.gov/38477755/
智鼠故事 
